Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalIt reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex.
Products: TACROLIMUS 3MG CAPSULAS DURAS DE LIBERACIÓN PROLONGADAAluminum zirconium octachlorohydrex gly
go.drugbank.com/drugs/DB11200ApprovedAluminum zirconium octachlorohydrex gly is complex that consists of aluminum zirconium octachlorohydrate and glycine. It is an active antiperspirant agent , . It diffuses into the sweat pores and prevents perspiration (sweat) from leavin...
Products: Secret Australia Eucalyptus Blossoms Clear, Secret Australia Eucalyptus Blossom InvisibleAtaluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications.
Conjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigationalBoth of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble. … The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material.
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigational[saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself … [A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]
Mixtures: LOPARTA® 40MG/10MG, RITOPIN® 200MG/50MGOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigational[A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Mixtures: VOCADO 40MG/10MG, VOCADO 40MG/10MGProducts: VOTUM 10MG, VOTUM 20MGEdoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawn[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.
Azithromycin
go.drugbank.com/drugs/DB00207ApprovedInvestigationalIt was initially approved by the FDA in 1991 [A174175]. … In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine].
Acarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigational[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels.
Products: GLUCOBAY TABLET 50MG, Gacose Tablet 50mg